tbuckley/cabot-search huggingface dataset:
Abstract 9509: Is Left Ventricular Lead Placement at Site of Latest Mechanical Activation Associated with Cardiac Resynchronization Therapy Outcomes? Results of a Meta-Analysis
Authors: Nancy M Allen Lapointe, Fatima Ali-ahmed, Frederik Dalgaard, Andrzej S Kosinski, Gillian D Sanders, Sana M Al-Khatib
Journal: Circulation (2021)

Introduction: CRT outcomes with image-guided left ventricular (LV) lead placement within the LV segment of latest mechanical activation have been assessed in several randomized controlled trials (RCTs) with equivocal results, possibly due to variable achievement of concordant LV lead placement in the image-guided and comparator arms. We conducted meta-analyses to assess CRT outcomes associated with concordant LV lead placement. Methods: A systematic literature review was performed to identify RCTs and prospective observational studies of CRT from October 2008 through October 2020 that reported outcomes in those with LV lead placement at or adjacent to the site of latest mechanical activation (concordant) versus those with LV lead placement distant to the site of latest mechanical activation (discordant) as determined by any imaging method. Two independent reviewers screened titles and abstracts then reviewed full text for inclusion/exclusion. One reviewer abstracted data and a second over-read for accuracy. Meta-analyses for death, death or HF hospitalization, and changes in LVESV and LVEF were performed using random effects models. Results: Among 5715 citations identified, 9 papers from 8 studies (including 4 RCTs) were selected that included 1004 patients with concordant LV lead placement and 380 with discordant LV lead placement. Mean patient age ranged from 66 to 68 years, 82% were male, and 64% had ischemic cardiomyopathy. Segment of latest activation was determined by speckle tracking echocardiography (STE) in 7 (88%) studies. Meta-analyses demonstrated statistically significant lower all-cause mortality or HF hospitalization and reduction in LVESV with a concordant LV lead (Figure). There were trends toward lower all-cause mortality and increased LVEF. Conclusion: A concordant LV lead, as determined primarily by STE, was associated with better CRT outcomes. Further study of feasible methods to achieve concordance in clinical practice is needed.
Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children
Authors: Kenney Ng, Harry Stavropoulos, Vibha Anand, Riitta Veijola, Jorma Toppari, Marlena Maziarz, Markus Lundgren, Kathy Waugh, Brigitte I. Frohnert, Frank Martin, William Hagopian, Peter Achenbach
Journal: Diabetes Care (2021)

OBJECTIVE To use islet autoantibody titers to improve the estimation of future type 1 diabetes risk in children. RESEARCH DESIGN AND METHODS Prospective cohort studies in Finland, Germany, Sweden, and the U.S. followed 24,662 children at increased genetic or familial risk to develop islet autoimmunity and diabetes. For 1,604 children with confirmed positivity, titers of autoantibodies against insulin (IAA), GAD antibodies (GADA), and insulinoma-associated antigen 2 (IA-2A) were harmonized for diabetes risk analyses. RESULTS Survival analysis from time of confirmed positivity revealed markedly different 5-year diabetes risks associated with IAA (n = 909), GADA (n = 1,076), and IA-2A (n = 714), when stratified by quartiles of titer, ranging from 19% (GADA 1st quartile) to 60% (IA-2A 4th quartile). The minimum titer associated with a maximum difference in 5-year risk differed for each autoantibody, corresponding to the 58.6th, 52.4th, and 10.2nd percentile of children specifically positive for each of IAA, GADA, and IA-2A, respectively. Using these autoantibody type-specific titer thresholds in the 1,481 children with all autoantibodies tested, the 5-year risk conferred by single (n = 954) and multiple (n = 527) autoantibodies could be stratified from 6 to 75% (P &amp;lt; 0.0001). The thresholds effectively identified children with a ≥50% 5-year risk when considering age-specific autoantibody screening (57–65% positive predictive value and 56–74% sensitivity for ages 1–5 years). Multivariable analysis confirmed the significance of associations between the three autoantibody titers and diabetes risk, informing a childhood risk surveillance strategy. CONCLUSIONS This study defined islet autoantibody type-specific titer thresholds that significantly improved type 1 diabetes risk stratification in children.
Materials-driven fibronectin assembly on nanoscale topography enhances mesenchymal stem cell adhesion, protecting cells from bacterial virulence factors and preventing biofilm formation
Authors: Laila A. Damiati, Monica P. Tsimbouri, Virginia-Llopis Hernandez, Vineetha Jayawarna, Mark Ginty, Peter Childs, Yinbo Xiao, Karl Burgess, Julia Wells, Mark R. Sprott, R.M. Dominic Meek, Peifeng Li, Richard O.C. Oreffo, Angela Nobbs, Gordon Ramage, Bo Su, Manuel Salmeron-Sanchez, Matthew J. Dalby
Journal: Biomaterials (2021)
The pathophysiology of Wilson’s disease visualized: A human 64Cu PET study
Authors: Thomas Damgaard Sandahl, Lars C. Gormsen, Kristoffer Kjærgaard, Mikkel Holm Vendelbo, Ditte Emilie Munk, Ole Lajord Munk, Dirk Bender, Susanne Keiding, Karina H. Vase, Kim Frisch, Hendrik Vilstrup, Peter Ott
Journal: Hepatology (2021)

Abstract Background and Aims Wilson’s disease (WD) is a genetic disease with systemic accumulation of copper that leads to symptoms from the liver and brain. However, the underlying defects in copper transport kinetics are only partly understood. We sought to quantify hepatic copper turnover in patients with WD compared with heterozygote and control subjects using PET with copper‐64 ( 64 Cu) as a tracer. Furthermore, we assessed the diagnostic potential of the method. Approach and Results Nine patients with WD, 5 healthy heterozygote subjects, and 8 healthy controls were injected with an i.v. bolus of 64 Cu followed by a 90‐min dynamic PET scan of the liver and static whole‐body PET/CT scans after 1.5, 6, and 20 h. Blood 64 Cu concentrations were measured in parallel. Hepatic copper retention and redistribution were evaluated by standardized uptake values (SUVs). At 90 min, hepatic SUVs were similar in the three groups. In contrast, at 20 h postinjection, the SUV in WD patients (mean ± SEM, 31 ± 4) was higher than in heterozygotes (24 ± 3) and controls (21 ± 4; p &lt; 0.001). An SUV‐ratio of hepatic 64 Cu concentration at 20 and 1.5 h completely discriminated between WD patients and control groups ( p &lt; 0.0001; ANOVA). By Patlak analysis of the initial 90 min of the PET scan, the steady‐state hepatic clearance of 64 Cu was estimated to be slightly lower in patients with WD than in controls ( p = 0.04). Conclusions 64 Cu PET imaging enables visualization and quantification of the hepatic copper retention characteristic for WD patients. This method represents a valuable tool for future studies of WD pathophysiology, and may assist the development of therapies, and accurate diagnosis.
Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
Authors: Koji Sasaki, Elias J. Jabbour, Ghayas C. Issa, Kiran Naqvi, Jeffrey Skinner, Kristin Anderson, Sara E Dellasala, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip A. Thompson, Yesid Alvarado, Nitin Jain, Guillermo Garcia-Manero, Koichi Takahashi, Jan A. Burger, Gautam Borthakur, Naveen Pemmaraju, Fadi Haddad, Maria R Khouri, Shilpa Paul, Sherry A. Pierce, Jorge E. Cortes, Hagop Kantarjian
Journal: Blood (2021)
Abstract 9176: Quarterly versus Annual ECG Screening for Atrial Fibrillation in Older Chinese (AF-CATCH): A Prospective, Randomised, Controlled Trial
Authors: Wei Zhang, Yi Chen, Jiguang Wang
Journal: Circulation (2021)

Introduction: Screening for atrial fibrillation before symptoms manifested and subsequent initiation of oral anticoagulants (OACs), could prevent stroke and death. The most cost-effective strategy to screen atrial fibrillation in high-risk population aged 65 and over remains unknown. Methods: We performed a randomised controlled trial that compares different screening frequencies of 30-second single-lead ECG (AliveCor® Heart Monitor) in the detection of atrial fibrillation in Chinese residents (≥65 years old) in 5 community health centres in Shanghai. Only participants without atrial fibrillation history and atrial fibrillation rhythm at baseline were eligible for inclusion in the trial. Participants were randomised in a 1:1 ratio into annual (G1) and quarterly screening (G2) groups: the quarterly screening group was further randomised in a 3:1 ratio into subgroups of quarterly screening (G2-1) and quarterly screening PLUS (G2-2, ECG weekly for 1-month then quarterly). The primary outcome was the detection rate of atrial fibrillation. The intention-to-treat analysis was performed for all randomised patients who had at least one ECG recording during follow-up. This trial was registered at ClinicalTrials.gov, number NCT02990741. Results: Between April 17, 2017, and June 26, 2018, a total of 8240 participants were randomised into G1 (n=4120), G2-1 (n=3090) and G2-2 (n=1030), with a mean of 1.6, 3.5 and 5.2 ECG records respectively during a median of 2.1 years follow-up (13,284 person-years). 73 incident cases of atrial fibrillation occurred: 26 in G1 (4.1/1000 person-years) and 47 in G2 (6.7/1000 person-years; hazard ratio with G1, 1.71; 95% confidence interval [CI] 1.06-2.76; P =0.03). 40 incident cases were detected in G2-1 (7.2/1000 person-years; hazard ratio with G1, 1.83; 95% CI 1.12-3.00; P =0.02) and 7 in G2-2 (4.8/1000 person-years; hazard ratio with G1, 1.24; 95% CI 0.54-2.86; P =0.61). No significant difference was noted between G2-1 and G2-2 (hazard ratio with G2-1, 0.68; 95% CI 0.30-1.52; P =0.35). Conclusions: Quarterly 30-second single-lead ECG screening significantly increased the detection rate of incident atrial fibrillation, additional weekly screening in the first month did not yield added predictive value.
Cell-Type and Allele Specific Distribution of Multiple <i>TET2</i> Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML)
Authors: Terra Lasho, Christy Finke, Michael M. Timm, Robert Durruthy-Durruthy, Marc Arribas-Layton, Mrinal M. Patnaik, Ayalew Tefferi, Naseema Gangat, Abhishek A. Mangaonkar, Moritz Binder, Alexandre Gaspar Maia, Wazim Mohammed Ismail, Matthew T Howard, Nicholas Chia
Journal: Blood (2021)
EXTH-68. DUAL METABOLIC REPROGRAMMING BY ONC201/TIC10 AND 2-DEOXYGLUCOSE HAS A STRONG ANTIPROLIFERATIVE EFFECT ON MEDULLOBLASTOMA CELLS
Authors: Annika Dwucet, Qiyu Cao, Maximilian Pruss, Mike-Andrew Westhoff, Christian Rainer Wirtz, Markus D Siegelin, Georg Karpel-Massler
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Medulloblastoma represents one of the most common brain tumors in children. While the understanding of the molecular characteristics of this disease has very much advanced, more efficient and less toxic therapeutics are still in high demand. In this study we examined whether the imipridone ONC201/TIC10 affects the metabolic and proliferative activity of medulloblastoma cells alone and in combination with 2-Deoxyglucose in vitro. METHODS Extracellular flux (agilent seahorse) and Western blot analyses were performed to assess effects on tumor cell metabolism and the expression of proteins of the respiratory chain in established medulloblastoma cells. MTT assays and spheroid assays were performed to examine anti-proliferative effects in a 2-D and 3-D setting. RESULTS Treatment with ONC201/TIC10 has a strong inihibitory effect on the cellular viability of different medulloblastoma cells independent of c-Myc expression. While ONC201/TIC10 decreases the oxidative consumption rates in D458 (c-Myc high) and DAOY (c-Myc low) cells, extracellular acidification rates experienced an increase in D458 and a decrease in DAOY cells. Treatment with ONC201/TIC10 in combination with the glycolysis inhibitor 2-Deoxyglucose synergistically inhibited the cellular viability of medulloblastoma cells and impaired the growth of spheroids. CONCLUSION Overall, ONC201/TIC10 profoundly inhibits the proliferative activity of medulloblastoma cells in a c-Myc-independent manner. Additional treatment with the glycolysis inhibitor 2-Deoxyglucose synergistically enhances the anti-medulloblastoma activity of ONC201/TIC10. This promising approach warrants further investigations.
Rectally shed SARS-CoV-2 in COVID-19 inpatients is consistently lower than respiratory shedding and lacks infectivity
Authors: Rune Micha Pedersen, Ditte Sandfeld Tornby, Line Lundegård Bang, Lone Wulff Madsen, Marianne Nielsine Skov, Thomas Vognbjerg Sydenham, Kat Steinke, Thøger Gorm Jensen, Isik Somuncu Johansen, Thomas Emil Andersen
Journal: Clinical Microbiology and Infection (2021)

ObjectivesAssessment of whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been propagated during intestinal passage and infectivity is conserved when shed rectally by hospitalized individuals.MethodsAn exploratory cohort study including 28 inpatients with coronavirus disease 2019 with estimation of RNA levels by RT-PCR and of viral infectivity by culturing of viral material sampled concomitantly and identically from pharynx and rectum.ResultsSARS-CoV-2 RNA was detected more frequently (91%, 30/33 versus 42%, 14/33, p <0.0001) and at higher concentrations (median levels 2 190 186 IU/mL versus 13 014 IU/mL, p <0.0001) in the pharyngeal swabs than in the rectal swabs. For all sample pairs (n = 33) the rectal swabs contained undetectable or lower SARS-CoV-2 RNA concentrations than their paired pharyngeal swabs. Replicative virus was found in 37% (11/30) of the PCR-positive pharyngeal swabs, whereas none of the PCR-positive rectal swabs could be cultured (0%, 0/14) despite containing SARS-CoV-2 RNA concentrations up to 1 544 691 IU/mL.ConclusionsOur data draw into question whether SARS-CoV-2 is transmitted readily from faeces.
Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)
Authors: Stefano Luminari, Maria Elena Nizzoli, Annalisa Chiarenza, Donato Mannina, Alessandra Tucci, Carola Boccomini, Lucia Farina, Jacopo Olivieri, Luigi Marcheselli, Simone Ferrero, Luca Arcaini, Alessandro Pulsoni, Gerardo Musuraca, Catello Califano, Michele Merli, Alessia Bari, Annarita Conconi, Francesca Re, Monica Balzarotti, Marco Ladetto, Caterina Patti, Antonello Pinto, Maria Giuseppina Cabras, Pellegrino Musto, Guido Gini, Annalisa Arcari, Martina Manni, Annibale Versari, Massimo Federico
Journal: Blood (2021)
Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials
Authors: Gordon Cook, Charlotte Pawlyn, Kara-Louise Royle, Amy Beth Coulson, Jennifer Bird, Stella Bowcock, Matthew W Jenner, Bhuvan Kishore, Christopher Parrish, Neil K Rabin, Phillip Best, Sharon Gillson, Rowena Henderson, Catherine Olivier, Martin F. Kaiser, Ruth M. de Tute, Roger G Owen, Mark T Drayson, John R Jones, Bryony Dawkins, David Meads, David Cairns, Graham Jackson
Journal: Blood (2021)
Abstract 10945: Risk Stratification and Prediction of Acute Myocardial Infarction Events Patients of Connective Tissue Disorders
Authors: Mohamed M Gad, Omar M Abdelfattah, Agam Bansal, Toshiaki Isogai, Soumya Chatterjee, Paul Cremer, Samir R Kapadia, Venu Menon, heba wassif
Journal: Circulation (2021)

Introduction: Connective tissue disorders (CTD) play an important role in the pathogenesis of atherosclerotic heart disease with a dynamic interplay between inflammatory and traditional cardiovascular risk factors. Hypothesis: We aim to develop, validate, and compare population-level machine learning models to predict the first acute myocardial infarction (AMI) event in CTD. Methods: We extracted patient data from the Healthcare Cost and Utilization Project (HCUP) and identified 62 demographic and clinical variables. We identified those with systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, mixed connective tissue disorder, Sjogren’s syndrome, polymyositis, and dermatomyositis. We excluded those with prior history of myocardial infarction, known coronary artery disease, or missing key variables. We split the records randomly into training (70%) and testing (30%) datasets. Keras sequential model with Adadelta optimizer was used to compile the deep neural network model and scikit-learn classifiers were used for machine learning models. We estimated model performance based on the area under the receiver-operator characteristics curve (AUC). Results: 961,405 records were identified, and out of these, 14,961 (1.6%) had the first AMI event. The neural network model performed best in predicting AMI with an AUC:0.96 [A]. Classifier models had varying degrees of success range from 0.71 to 0.86 with Gradient Boosting Classifier, AUC:0.86 [B], being the best performing classifier, followed by Decision Tree, AUC:0.85, Logistic regression, AUC:0.84, Random Forest, AUC:0.84, Naive Bayes, AUC:0.75, Stochastic Gradient Descend, AUC: 0.71. Conclusions: A neural network model was able to predict the first AMI in people with CTD accurately. Developing and implementing machine learning models can help clinicians predict individual patient risk with a high degree of success.
Abstract 9343: Dietary Fat Intake and the Risk of Stroke: Results from Two Prospective Cohort Studies
Authors: Fenglei Wang, Megu Y Baden, Kathryn M Rexrode, Frank B Hu
Journal: Circulation (2021)

Background: The association between specific types of fat intake and the risk of stroke remains inconclusive. Prospective data examining the relation of fat from different food sources to stroke risk are sparse. We aimed to investigate the association between total fat, various types of fat, and fat from different sources and the risk of stroke. Methods: We followed 73,867 women (Nurses’ Health Study, 1984-2016) and 43,269 men (Health Professionals Follow-up Study, 1986-2016) free of cardiovascular disease and cancer at baseline. Dietary fat intake was collected by food-frequency questionnaires and categorized by sources and types. Cox proportional hazards models were used to assess the association between fat intake and stroke risk. Results: During 3,168,151 person-years of follow-up, we documented 6,189 incident stroke events (including 2,967 ischemic and 814 hemorrhagic). A high intake of vegetable fat (HR comparing extreme quintiles=0.88; 95% CI: 0.81, 0.96; P-trend&lt;0.001) or polyunsaturated fat (HR=0.88; 95% CI: 0.80, 0.96; P-trend=0.002) was associated with lower total stroke risk, whereas high non-dairy animal fat was associated with an increased risk (HR=1.16; 95% CI: 1.05, 1.29; P-trend&lt;0.001). We observed similar associations for the ischemic stroke, but only the positive association of non-dairy animal fat was observed for the hemorrhagic stroke. For food groups contributing to fat intake, vegetable oil (HR per 1 serving/day=0.91; 95% CI: 0.84, 0.98) was associated with lower total stroke risk, while total red meat (HR=1.08; 95% CI: 1.02, 1.13) and processed red meat (HR=1.12; 95% CI: 1.03, 1.23) were associated with a higher risk. The association for vegetable oil was attenuated after adjusting for vegetable fat or polyunsaturated fat, while adjusting for non-dairy animal fat rendered total red meat and processed red meat nonsignificant. Conclusions: A higher intake of vegetable fat, polyunsaturated fat, and vegetable oil was associated with a reduced risk of stroke, but a high intake of non-dairy animal fat, total red meat, and processed red meat was associated with increased stroke risk. These findings indicate the importance of considering the fat sources when examining the association between fat and stroke.
Iron Repletion Increases Platelet Aggregation and Reduces Platelet Count in Iron Deficient Premenopausal Women
Authors: Benjamin Elstrott, Hari H.S. Lakshmanan, Hannah Stowe McMurry, Malinda T West, Sven Reid Olson, Thomas G. Deloughery, Joseph Aslan, Joseph J Shatzel
Journal: Blood (2021)
The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse
Authors: John R Jones, Charlotte Pawlyn, Niels Weinhold, Timothy Cody Ashby, Brian A Walker, Christopher P. Wardell, David Cairns, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Mark T Drayson, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan
Journal: Blood (2021)
CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM
Authors: Pierre Peterlin, Pascal Turlure, Patrice Chevallier, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Anna Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose Miguel Torregrosa Diaz, Louis Devron, Sylvie Chevret, Marie C Bene, Yannick Le Bris, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Pierre Fenaux
Journal: Blood (2021)
Abstract PO-129: Targeting CCR1 reprograms tumor associated macrophages in pancreatic cancer
Authors: Yaqing Zhang, Kristee L. Brown, Wei Yan, Zeribe C. Nwosu, Eileen K. Carpenter, Katelyn L. Donahue, Ashley Velez-Delgado, Sion Yang, Marina Pasca di Magliano
Journal: Cancer Research (2021)

Abstract The tumor microenvironment of pancreatic ductal adenocarcinoma (PDA) includes abundant fibroblasts and infiltrating immune cells, the latter largely immunosuppressive. We previously showed that targeting regulatory T cell (Treg), a prevalent T cell population in pancreatic cancer, failed to relieve immunosuppression and led to accelerated tumor progression. We discovered that Treg depletion reprogrammed tumor associated fibroblasts and increased immunosuppressive myeloid cell recruitment, an effect that was partially mediated by CCLs/CCR1signaling. Thus, we sought to investigate the potential therapeutic effect of targeting CCR1 in pancreatic cancer. By single cell RNA sequencing, we found CCR1 to be mainly expressed by tumor associated macrophages (TAMs) and neutrophils (or granulocytes) in both human and mouse PDA. We then orthotopically transplanted syngeneic mouse pancreatic cancer cells in CCR1 knockout hosts, and observed reduced tumor growth which was rescued by CD8 T cell depletion. Histological analysis showed elevated Granzyme B expression in infiltrating T cells, as well as an increase in cleaved caspase 3 positive cancer cells in tumors implanted in Ccr1−/− mice. Through cytometry by time of flight (CyTOF) and co-immunofluorescence we also discovered that TAMs in tumors implanted in Ccr1−/− mice expressed less Arginase 1 and CD206 -both markers of immunosuppressive macrophages- compared to TAMs in wild type tumors. Thus, our data is consistent with the notion that tumor associated macrophages lacking CCR1 expression are less immunosuppressive, consequently allowing increased CD8 T cell-mediated anti-tumor immunity. We are currently exploring combination approaches targeting CCR1 in pancreatic cancer. Citation Format: Yaqing Zhang, Kristee L. Brown, Wei Yan, Zeribe C. Nwosu, Eileen K. Carpenter, Katelyn L. Donahue, Ashley Velez-Delgado, Sion Yang, Marina Pasca di Magliano. Targeting CCR1 reprograms tumor associated macrophages in pancreatic cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-129.
Optimizing pharmacokinetics and targeting properties of recombinant anti-Lewis Y antibody hu3S193 in A431 tumor bearing mice
Authors: Ingrid J Burvenich, FT Lee, Graeme O'Keefe, Dahna Makris, Paul A Ramsland, Zhanqi Liu, Laura Allan, Angelo Perani, Glenn Cartwright, Diana Cao, Angela Rigopoulos, Sylvia Gong, Benjamin Gloria, Roger Murphy, Andrew M Scott
Journal: Cancer Research (2011)